Literature DB >> 14508296

Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness.

James Waxmonsky1.   

Abstract

PURPOSE OF REVIEW: Attention deficit hyperactivity disorder (ADHD) frequently occurs with a wide variety of comorbid psychiatric disorders such as conduct disorder, depression, mania, anxiety, and learning disabilities. Because the vast majority of children with ADHD are treated in primary care settings, it is important that primary medical doctors be proficient in the diagnosis and initial treatment of children with ADHD and its commonly occurring comorbid disorders. ADHD research is beginning to focus on the treatment of these comorbidly ill children. This review will summarize the recent findings from the psychiatric literature in an attempt to provide the clinician with some initial diagnostic and treatment guidelines for ADHD and its comorbidities. RECENT
FINDINGS: The NIMH Multimodal Treatment Study of ADHD found that children with other disruptive behavior disorders plus ADHD respond well to stimulant medications, with behavioral interventions reducing academic and social impairment. Children with anxiety and ADHD are very responsive across multiple dimensions to behavioral and pharmacological ADHD treatments. Much less is known about the impact of depression on ADHD, and significant debate exists surrounding the identification and treatment of bipolar disorder in children with ADHD. Children with learning disabilities respond well to stimulants but often require additional educational supports. New findings suggest that treating ADHD may prevent the development of future psychiatric disorders.
SUMMARY: The presence of comorbid illness is associated with significant additional morbidity and complicates the diagnosis, treatment, and prognosis of ADHD. Therefore, it is important to identify and treat any comorbid psychiatric conditions in a child with ADHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508296     DOI: 10.1097/00008480-200310000-00006

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  19 in total

1.  Co-existing symptoms and risk factors among African school children with hyperactivity-inattention symptoms in Kinshasa, Congo.

Authors:  Espérance Kashala; Astri Lundervold; Kristian Sommerfelt; Thorkild Tylleskär; Irene Elgen
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-03-31       Impact factor: 4.785

2.  Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood.

Authors:  Brandon L Warren; Sergio D Iñiguez; Lyonna F Alcantara; Katherine N Wright; Eric M Parise; Sarah K Weakley; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2011-07-13       Impact factor: 6.167

3.  Differentiating major depressive disorder in youths with attention deficit hyperactivity disorder.

Authors:  Rasim Somer Diler; W Burleson Daviss; Adriana Lopez; David Axelson; Satish Iyengar; Boris Birmaher
Journal:  J Affect Disord       Date:  2007-02-05       Impact factor: 4.839

4.  Effects of psychotropic drugs on second messenger signaling and preference for nicotine in juvenile male mice.

Authors:  Lyonna F Alcantara; Brandon L Warren; Eric M Parise; Sergio D Iñiguez; Carlos A Bolaños-Guzmán
Journal:  Psychopharmacology (Berl)       Date:  2014-01-23       Impact factor: 4.530

Review 5.  New directions for the treatment of depression: Targeting the photic regulation of arousal and mood (PRAM) pathway.

Authors:  Hannah E Bowrey; Morgan H James; Gary Aston-Jones
Journal:  Depress Anxiety       Date:  2017-05-10       Impact factor: 6.505

6.  The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes.

Authors:  David Alter; Joel A Beverley; Ronak Patel; Carlos A Bolaños-Guzmán; Heinz Steiner
Journal:  J Psychopharmacol       Date:  2017-07-18       Impact factor: 4.153

7.  Database analysis of children and adolescents with bipolar disorder consuming a micronutrient formula.

Authors:  Julia J Rucklidge; Dermot Gately; Bonnie J Kaplan
Journal:  BMC Psychiatry       Date:  2010-09-28       Impact factor: 3.630

Review 8.  Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior.

Authors:  Heinz Steiner; Brandon L Warren; Vincent Van Waes; Carlos A Bolaños-Guzmán
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

9.  Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?

Authors:  W Burleson Daviss; Boris Birmaher; Rasim S Diler; James Mintz
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-06       Impact factor: 2.576

Review 10.  Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

Authors:  Johnny Graham; David Coghill
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.